Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × NIH × Miransertib × Clear all

Phase

Status

Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Proteus Syndrome 1

Interventions

Specimen Handling 113 Magnetic Resonance Spectroscopy 76 Biopsy 67 Cyclophosphamide 22 pembrolizumab 20 fludarabine 17 Cisplatin 17 Nivolumab 15 Taxes 14 Platinum 14 1,2-diaminocyclohexaneplatinum II citrate 14 venetoclax 13 Paclitaxel 13 Immunoglobulin G 13 Disulfides 13 X-Rays 12 Radiation 11 Carboplatin 11 Doxorubicin 10 Radiotherapy 9 Gemcitabine 9 aldesleukin 8 Prednisone 8 olaparib 7 durvalumab 7 atezolizumab 7 trastuzumab deruxtecan 6 lutetium Lu 177 dotatate 6 gallium Ga 68 dotatate 6 decitabine and cedazuridine drug combination 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04316546 2026-03-11

MK-7075 (Miransertib) in Proteus Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting

Proteus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡